Clinical Trial Update: Duvelisib for Ibrutinib-Resistant Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma [Phase 2]

View source ↗

Summary

Phase 2 trial of duvelisib in ibrutinib-resistant CLL/SLL was terminated; results posted in 2022.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Lymphocytic Leukemia
• Small Lymphocytic Leukemia

Drugs mentioned

• Duvelisib (duvelisib)

Snippet

Sponsor: National Heart, Lung, and Blood Institute (NHLBI) | Conditions: Small Lymphocytic Leukemia (SLL), Chronic Lymphocytic Leukemia (CLL) | Phase 2 | Status: TERMINATED | Results posted: 2022-03-09